Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.

Jendle, Johan et al.·Diabetes/metabolism research and reviews·2016·
RPEP-029782016RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Published In:
Diabetes/metabolism research and reviews, 32(8), 776-790 (2016)
Database ID:
RPEP-02978

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-02978·https://rethinkpeptides.com/research/RPEP-02978

APA

Jendle, Johan; Grunberger, George; Blevins, Thomas; Giorgino, Francesco; Hietpas, Ryan T; Botros, Fady T. (2016). Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.. Diabetes/metabolism research and reviews, 32(8), 776-790. https://doi.org/10.1002/dmrr.2810

MLA

Jendle, Johan, et al. "Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.." Diabetes/metabolism research and reviews, 2016. https://doi.org/10.1002/dmrr.2810

RethinkPeptides

RethinkPeptides Research Database. "Efficacy and safety of dulaglutide in the treatment of type ..." RPEP-02978. Retrieved from https://rethinkpeptides.com/research/jendle-2016-efficacy-and-safety-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.